Evonik Evonik

X

CAS 104746-04-5 manufacturers and suppliers on PharmaCompass

PharmaCompass
CAS 104746-04-5
Also known as: 104746-04-5, (s)-licarbazepine, (s)-10-hydroxy-10,11-dihydro-5h-dibenzo[b,f]azepine-5-carboxamide, Bia 2-194, S(+)-liscarbazepine, S-10-monohydroxy-dihydro-carbamazepin
Molecular Formula
C15H14N2O2
Molecular Weight
254.28  g/mol
InChI Key
BMPDWHIDQYTSHX-AWEZNQCLSA-N
FDA UNII
S5VXA428R4

Adjunctive Therapy for Adults with Partial-Onset Seizures
The mechanism of action of eslicarbazepine is as a Cytochrome P450 3A4 Inducer, and Cytochrome P450 2C19 Inhibitor. The physiologic effect of eslicarbazepine is by means of Decreased Central Nervous System Disorganized Electrical Activity.
1 2D Structure

CAS 104746-04-5

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(5S)-5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide
2.1.2 InChI
InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)/t14-/m0/s1
2.1.3 InChI Key
BMPDWHIDQYTSHX-AWEZNQCLSA-N
2.1.4 Canonical SMILES
C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O
2.1.5 Isomeric SMILES
C1[C@@H](C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O
2.2 Other Identifiers
2.2.1 UNII
S5VXA428R4
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (10s)-10-hydroxy-10,11-dihydro-5h-dibenzo(b,f)azepin-5-carboxamide

2.3.2 Depositor-Supplied Synonyms

1. 104746-04-5

2. (s)-licarbazepine

3. (s)-10-hydroxy-10,11-dihydro-5h-dibenzo[b,f]azepine-5-carboxamide

4. Bia 2-194

5. S(+)-liscarbazepine

6. S-10-monohydroxy-dihydro-carbamazepin

7. Licarbazepine, (s)-

8. (s)-mhd

9. S5vxa428r4

10. Ec 810-248-9

11. (5s)-5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide

12. Bia-2-194

13. Cgp-13751

14. (10s)-10,11-dihydro-10-hydroxy-5h-dibenz(b,f)azepine-5-carboxamide

15. (10s)-10,11-dihydro-10-hydroxy-5h-dibenz[b,f]azepine-5-carboxamide

16. S-licarbazepine

17. (10s)-10-hydroxy-10,11-dihydro-5h-dibenzo(b,f)azepin-5-carboxamide

18. Eslicarbazepine [inn]

19. Unii-s5vxa428r4

20. (s)-(+)-10,11-dihydro-10-hydroxy-5h-dibenz[b,f]azepine-5-carboxamide

21. (eslicarbazepine)

22. (s)-(+)-10,11-dihydro-10-hydroxy-5h-dibenz(b,f)azepine-5-carboxamide

23. Eslicarbazepine [usan:inn:ban]

24. Monohydroxy Carbamazepine

25. S-(+)-10,11-dihydro-10-hydroxy-5h-dibenz[b,f]azepine-5-carboxamide

26. Eslicarbazepine [mi]

27. Eslicarbazepine (usan/inn)

28. Eslicarbazepine [usan]

29. Schembl418933

30. Eslicarbazepine [vandf]

31. Chembl315985

32. Gtpl7350

33. Eslicarbazepine [mart.]

34. Eslicarbazepine [who-dd]

35. Eslicarbazepine (bia 2-194)

36. Chebi:174358

37. Dtxsid901316900

38. Zinc896938

39. Akos016844866

40. Db14575

41. Hy-114703

42. Cs-0064132

43. D09215

44. (s)-10-monohydroxy-10,11-dihydro Carbamazepine

45. J-001242

46. Q27077226

47. (10s)-10-hydroxy-10,11-dihydro-5h-dibenzo[b,f]azepine-5 Carboxamide

48. (10s)-10-hydroxy-10,11-dihydro-5h-dibenzo[b,f]azepine-5-carboxamide

49. (s)-(+)-10-hydroxy-10,11-dihydro-5h-dibenz[b,f]azepine-5-carboxamide

50. 5h-dibenz[b,f]azepine-5-carboxamide,10,11-dihydro-10-hydroxy-,(10s)-

51. 5h-dibenz(b,f)azepine-5-carboxamide, 10,11-dihydro-10-hydroxy-, (10s)-

52. (s)-licarbazepine; (10s)-10,11-dihydro-10-hydroxy-5h-dibenz[b,f]azepine-5-carboxamide; S-(+)-10,11-dihydro-10-hydroxy-5h-dibenz[b,f]azepine-5-carboxamide

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 254.28 g/mol
Molecular Formula C15H14N2O2
XLogP31.4
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count2
Rotatable Bond Count0
Exact Mass254.105527694 g/mol
Monoisotopic Mass254.105527694 g/mol
Topological Polar Surface Area66.6 Ų
Heavy Atom Count19
Formal Charge0
Complexity347
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 FDA Pharmacological Classification
4.1.1 Active Moiety
ESLICARBAZEPINE
4.1.2 FDA UNII
S5VXA428R4
4.1.3 Pharmacological Classes
Mechanisms of Action [MoA] - Cytochrome P450 2C19 Inhibitors
4.2 ATC Code

N - Nervous system

N03 - Antiepileptics

N03A - Antiepileptics

N03AF - Carboxamide derivatives

N03AF04 - Eslicarbazepine


4.3 Mechanism of Action

The precise mechanism(s) by which eslicarbazepine exerts anticonvulsant activity is unknown but is thought to involve inhibition of voltage-gated sodium channels.


Flag India
Digital Content Digital Content
URL Supplier Web Content
29331-92-8
CTX is one of the youngest and fastest-growing Indian API and Intermediate manufacturing companies doing ...
CTX is one of the youngest and fastest-growing Indian API and Intermediate manufacturing companies doing business in over 70 countries. In these five years, all my thoughts and actions have been to enhance the life of my organization by serving the pharmaceutical industry with complete dedication. CTX is accredited with US FDA, EU GMP, PMDA Japan and COFEPRIS Mexico cGMP. The ultimate business strategy of CTX Life Sciences is “ to be a partner in the global pharmaceutical and chemical industries and continue to be a reliable and consistent supplier of APIs and Intermediates.
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Flag India
Digital Content Digital Content
URL Supplier Web Content
29331-92-8
ZCL Chemicals Ltd is an 100% Export Oriented Unit (EOU) that combines the power of science & technology. ...
ZCL Chemicals Ltd is an 100% Export Oriented Unit (EOU) that combines the power of science & technology. Established in 1991, the company head quarter is in Mumbai .The R&D Center and cGMP-manufacturing facility is in the Industrial heart of Ankleshwar city in Gujarat, 300 k.m. North of Mumbai, well connected by Road, Rail and Air enabling swift cargo movement to the nearest major sea/airport being Mumbai. The Company delivers a broad range of advance fine chemical intermediates and active.
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY